The Complete Guide to Nootropic Peptides

TL;DR

• Semax is an ACTH(4-7) analog with a real clinical history, largely Russian, and limited Western validation.
• Selank is a tuftsin analog studied as an anxiolytic on a similar Russian clinical base.
• The FDA's advisory committee recommended Semax 8–5 in July 2026 for the 503A list - a nonbinding recommendation, not approval, with rulemaking still pending. Selank was not on that docket.
• Dihexa is an angiotensin IV analog whose synaptogenesis case rests on animal findings, with no human efficacy trials.
• Cerebrolysin has genuine human trial data in stroke and dementia, but mixed and contested; it is used in some countries and is not FDA-approved.
• All four are investigational, and none is an FDA-approved cognitive treatment.

Educational content, not medical advice. No doses or protocols appear; any use is physician-directed with verified product. The compounds here are investigational, and none is an FDA-approved cognitive treatment.

---

"Nootropic peptides" is a category built as much on hope as on evidence. The compounds are real and some have a genuine clinical history - but that history is largely outside Western regulatory frameworks, the human trials are often small or dated, and the gap between "studied in a specific clinical population" and "will make a healthy person think better" is where most of the marketing lives. The honest framing: Semax and Selank sit at the front of the pack on evidence; Dihexa and Cerebrolysin are further back, with a thinner and more preclinical base; and all of them are investigational, supervised-use-only compounds - not shelf nootropics. This guide maps the field and routes you to the honest deep-dive on each.

What this guide covers

Start here

• Semax and Selank: the nootropic peptides, honestly - the two best-known cognitive peptides
• Is Semax legal in 2026? - where the July FDA vote leaves Semax, Selank and access
• Whether nootropic peptides cross the blood-brain barrier - the delivery question sitting underneath every claim on this page
• Nootropic peptides and the ageing brain - who the trials actually enrolled, and why the missing age-stratified data matters
• Peptides and mood: what the evidence actually says - why there is no peptide for happiness, and where the better-evidenced routes run
• Brain fog is not one problem - a description rather than a diagnosis, and how to describe it precisely enough to be explained
• When motivation and drive change during metabolic treatment - flat mood on a GLP-1, how to tell the causes apart, and why it belongs with your prescriber

The advanced compounds

• Dihexa and Cerebrolysin: beyond Semax and Selank - the higher-potency claims and thinner evidence
• Is Cerebrolysin approved outside the US? - authorised in 50+ countries, never FDA-reviewed, and why a count of jurisdictions is not an evidence grade

Related

• After the FDA vote: what changed · Which peptides are legal in 2026 · Peptides for sleep

The evidence spectrum (this is the map)

Semax and Selank lead on evidence - with caveats

Of the cognitive peptides, Semax and Selank have the most substantial clinical history, largely from Russian research and clinical use over decades. That history is real and worth taking seriously - and it is also not the same as the large, replicated, independently-validated Western trials that underpin approved drugs. Semax's recommendation by the FDA's advisory committee in July 2026 (an 8–5 vote) reflects growing regulatory attention, but a recommendation is not approval; what that vote changes for access is narrower than the headlines imply.

The advanced end runs ahead of the data

Dihexa and Cerebrolysin are where the evidence thins and the claims escalate. Dihexa's synaptogenesis story rests on striking animal findings and essentially no human trials; Cerebrolysin has genuine human trial data in stroke and dementia, but the results are mixed and the interpretation contested. Neither is a validated cognitive enhancer for healthy people, and the potency claims attached to them are a reason for more caution, not less.

FAQ

What are nootropic peptides? Peptides marketed for cognitive benefit - most prominently Semax and Selank, with Dihexa and Cerebrolysin at the more speculative end. All are investigational; none is an FDA-approved cognitive treatment.

Do they actually work? Semax and Selank have a real clinical history, mostly from Russian research, though Western validation is limited. The more advanced compounds have thinner, largely preclinical evidence. Effects in healthy people are far less established than the marketing suggests.

Are nootropic peptides legal? They're investigational and mostly sold "for research use only" in the US. Semax was recommended by an FDA advisory committee in July 2026, but that is not approval and does not change legal access yet.

---

Explore it with verified supply. Every Vivre Labs lot is independently tested and the certificate of analysis is published, so you know exactly what is in the vial. Explore Semax.

Educational content, not medical advice. Nootropic peptides are investigational; human evidence is limited and, for several, largely non-Western or preclinical. Any use is physician-directed with verified product; do not self-source peptides. Claims for the Malaysian market are subject to MAB requirements.

Key references

• Semax (ACTH(4-7) analog) and Selank (tuftsin analog): predominantly Russian clinical and preclinical literature; limited independent Western validation. · Dihexa (angiotensin IV analog): preclinical synaptogenesis findings; no human efficacy trials. · Cerebrolysin: human trials in stroke and vascular dementia, mixed/debated. · FDA PCAC, July 24, 2026: Semax recommended 8–5 for the 503A list; non-binding, rulemaking pending.